4 reports of this reaction
2.0% of all PHENDIMETRAZINE TARTRATE reports
#7 most reported adverse reaction
CHOROIDAL EFFUSION is the #7 most commonly reported adverse reaction for PHENDIMETRAZINE TARTRATE, manufactured by Acertis Pharmaceuticals, LLC. There are 4 FDA adverse event reports linking PHENDIMETRAZINE TARTRATE to CHOROIDAL EFFUSION. This represents approximately 2.0% of all 196 adverse event reports for this drug.
Patients taking PHENDIMETRAZINE TARTRATE who experience choroidal effusion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHOROIDAL EFFUSION is a less commonly reported adverse event for PHENDIMETRAZINE TARTRATE, but still significant enough to appear in the safety profile.
In addition to choroidal effusion, the following adverse reactions have been reported for PHENDIMETRAZINE TARTRATE:
CHOROIDAL EFFUSION has been reported as an adverse event in 4 FDA reports for PHENDIMETRAZINE TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHOROIDAL EFFUSION accounts for approximately 2.0% of all adverse event reports for PHENDIMETRAZINE TARTRATE, making it a notable side effect.
If you experience choroidal effusion while taking PHENDIMETRAZINE TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.